Clinical trials: Cutaneous Squamous Cell Cancer
Squamous Cell Carcinoma, Skin Cancer
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
- Conditions
- Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor
- Trial name
- NCT03714828
- Testing
- Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Arizona
Squamous Cell Carcinoma
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the…
- Trial name
- NCT00652080
- Testing
- API 31510
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- BPGbio
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
- Trial name
- NCT04710498
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in patients with squamous cell carcinoma of the skin.
- Trial name
- NCT02218164
- Testing
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04576091
- Testing
- Biospecimen Collection, Computed Tomography, Elimusertib
- Where
- 11 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body.
- Trial name
- NCT02964559
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Skin Cancer, Basal Cell Carcinoma
Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
The purpose of this study is to determine the difference of skin carotenoid levels between subjects with previous squamous cell carcinomas (SCC), subjects with previous basal cell carcinomas (BCC) and a control group.
- Conditions
- Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT00836342
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Skin Cancer
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma.
- Trial name
- NCT01059305
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
This is a single-arm, non-randomized pilot study to evaluate the efficacy and tolerability of combination quad-shot palliative radiotherapy with immunotherapy for advanced/recurrent/metastatic head and neck cancer.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04454489
- Testing
- Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Cutaneous Squamous Cell Carcinoma
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
- Trial name
- NCT02760498
- Testing
- cemiplimab
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 432 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous…
- Trial name
- NCT04502888
- Testing
- Drug: SL-172154
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Shattuck Labs, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection…
- Trial name
- NCT00911326
- Testing
- Lymphoseek
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Navidea Biopharmaceuticals
Cancer
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
This is a phase II study designed to study the effectiveness of combined radiotherapy and erlotinib in the postoperative setting for patients with cutaneous SCC that are at high risk for recurrence.
- Trial name
- RAD0503 (NCT00369512)
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Facial isSCC
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
Open label, dose escalation to evaluate safety.
- Trial name
- isSCC (NCT05421013)
- Testing
- STP705
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sirnaomics
Cutaneous Squamous Cell Carcinoma
Treatment With Nab-paclitaxel in Cutaneous SCC
This is an investigator initiated phase II study to assess the efficacy of a chemotherapy called nab-paclitaxel as first line cytotoxic chemotherapy in subjects with unresectable locally advanced or metastatic cutaneous squamous…
- Trial name
- NCT02076243
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc